- Category
- Micro (2020-21)
- Udyam number
- UDYAM-UP-75-0006793

Ulisses Pharmaceuticals Private Limited
About Ulisses Pharmaceuticals Private Limited
Data last updated:
Ulisses Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 23 January 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24290DL2021PTC376099.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹4 Lakh. It is led by directors Shashikala Upadhyay and Mahi Upadhyay.
Its last annual general meeting (AGM) was held on 21 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at T – 786 – A – 1 G/F Prem Nagar, Baljeet Nagar(Bnc – 0976), New Delhi, Delhi, India – 110008.
As per the financials filed for FY 2025, the company reported a revenue of ₹34.2 Lakh, a decline of 7% compared to the previous year. For the same year it recorded a net loss of ₹2.4 Lakh (net margin -7%) and EBITDA of -₹2.4 Lakh (EBITDA margin -7%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years.
The company has about 6 employees on its provident fund (EPFO) records.
Ulisses Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-75-0006793). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Recognitions & Rankings of Ulisses Pharmaceuticals
Contact details
Ulisses Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi.
- Registered AddressT – 786 – A – 1 G/F Prem Nagar, Baljeet Nagar(Bnc – 0976), New Delhi, Delhi, India – 110008
- IndustryChemicals, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ulisses Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Ulisses Pharmaceuticals Private Limited, buy the company report.
Financials of Ulisses Pharmaceuticals Private Limited
FY 2025 filings availableUlisses Pharmaceuticals Private Limited reported revenue of ₹34.2 Lakh (down 7% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 7% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 8%. EBITDA fell 145% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2.4 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.4 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -7% | ||||
| Net Profit Margin | -7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Ulisses Pharmaceuticals Private Limited, buy the company report.
Board of directors of Ulisses Pharmaceuticals Private Limited
Ulisses Pharmaceuticals has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shashikala Upadhyay | Director | 23 Jan 2021 | 5 Years 9 Months | Current |
| Mahi Upadhyay | Director | 29 Nov 2025 | 0 Years 11 Months | Current |
Legal cases
No court or tribunal cases involving Ulisses Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ulisses Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Ulisses Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Ulisses Pharmaceuticals Private Limited has 5 board changes on record since 2021: 3 appointments and 2 cessations. The latest: Mahi Upadhyay was appointed as Director on 29 Nov 2025.
Frequently asked questions
Ulisses Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 23 January 2021 (5+ years old) and is registered under CIN U24290DL2021PTC376099.
Ulisses Pharmaceuticals has 2 current directors:
- Shashikala Upadhyay - Director
- Mahi Upadhyay - Director
The latest financial statements of Ulisses Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 21 August 2025. Year-wise statements from FY 2021 are in the company report.
The CIN (Corporate Identification Number) of Ulisses Pharmaceuticals is U24290DL2021PTC376099. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ulisses Pharmaceuticals was incorporated on 23 January 2021, making it 5+ years old. It is registered with the Registrar of Companies, Delhi.
Mahi Upadhyay was appointed as Director on 29 Nov 2025. Diwaker Mishra ceased to be Director on 29 Dec 2022. Sarita Sahi ceased to be Director on 29 Dec 2022. Ulisses Pharmaceuticals has 5 board changes on record in total.
Yes, Ulisses Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-UP-75-0006793).
The registered office of Ulisses Pharmaceuticals is at T – 786 – A – 1 GF Prem Nagar, Baljeet NagarBnc – 0976, New Delhi, Delhi, India – 110008.
Ulisses Pharmaceuticals operates in the chemicals industry, in the manufacturing segment.
The compliance status of Ulisses Pharmaceuticals is compliant as of 20 August 2026. The company is actively filing with the Registrar of Companies.

